Bristol Myers Squibb vs Viatris
Bristol Myers Squibb (BMY) and Viatris (VTRS) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $122B
- Last close
- $59.56
- 12 months
- +26.6%
- Market value
- $21.5B
- Last close
- $20.45
- 12 months
- +91.8%
At a glance
- By market value, Bristol Myers Squibb ($121.7B) is about 5.7 times Viatris ($21.5B).
- Over the last 12 months Bristol Myers Squibb's share price moved +26.6% and Viatris's +91.8%; against the S&P 500 that is +15.9 points and +81.8 points.
- In the last 90 days insiders reported 0 open-market purchases at Bristol Myers Squibb and 0 at Viatris; members of Congress disclosed 0 trades in Bristol Myers Squibb and 0 in Viatris.
- Next results: Bristol Myers Squibb Feb 3, 2027, Viatris Feb 24, 2027.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Bristol Myers Squibb BMYNYSE · Pharmaceuticals | Viatris VTRSNASDAQ · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $122B | $21.5B |
| Revenue, last fiscal year | $48.2B | $14.3B |
| Net income, last fiscal year | $7.05B | — |
| Net marginNet income as a share of revenue | 14.6% | — |
| Free cash flow | $12.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Bristol Myers Squibb against
Common questions
How do Bristol Myers Squibb and Viatris compare in size?
Bristol Myers Squibb has the larger market value: Bristol Myers Squibb $122B and Viatris $21.5B, at the last close.
Whose share price rose more over the last 12 months, BMY or VTRS?
Over the last 12 months Bristol Myers Squibb moved +26.6% and Viatris +91.8%. Past price moves say nothing about the future.
Which has had more insider buying, Bristol Myers Squibb or Viatris?
Since 2006, Bristol Myers Squibb insiders reported 47 open-market purchases against 10 for Viatris. These are counts of what was filed, not a view on either stock.
Do members of Congress trade BMY or VTRS?
In the last 12 months, members of Congress disclosed 8 trades in Bristol Myers Squibb (BMY) and 1 in Viatris (VTRS).
When did insiders last buy BMY and VTRS?
Bristol Myers Squibb: Apr 29, 2025. Viatris: Mar 10, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Bristol Myers Squibb pageViatris pageRare insider trades this weekAll comparisons
https://oqro.io/compare/bmy-vs-vtrs






